GROWBLOX SCIENCES INC (GBLX)

GBLX
Symbol Name Last Trade Price Change Change (%) Volume




Revenue 1 year Target Price 52 week Range Stock Exchange Last Trade Size

Growblox Sciences, Inc. (Growblox) is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. The Company seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. Growblox intends to conduct its business operations, through its subsidiaries, in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB (collectively, the GrowBLOX Suites). The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.

Breaking News Arrows

Breaking News

  • GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease FormulationsDecember 20, 2019GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council (NRC) in Halifax, Nova Scotia, CANADA. GB Sciences' PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of Parkinson's disease in the animal model. Our final phase of testing will study the mechanism of action for these promising formulations, which could potentially help patients with this debilitating disease. The combined direct and indirect costs associated with Parkinson's disease are estimated at $52 billion in the U.S. alone.
  • GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic PainDecember 5, 2019LAS VEGAS , Dec. 5, 2019 /CNW/ — GB Sciences, Inc. (GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production operation. This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company to focus solely on its biopharmaceutical and wellness assets. The transaction is the next step in the Company's exit from cannabis cultivation and production.
  • GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development AgreementNovember 18, 2019The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana. LAS VEGAS, Nov. 18, 2019 /PRNewswire/ — GB Sciences, Inc. (GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns the other 50% interest. The sale immediately eliminates current cash obligations due from GB Sciences as well as the Company's share of operating expenses going forward.
  • The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is DelayedNovember 6, 2019LAS VEGAS, Nov. 6, 2019 /PRNewswire/ — GB Sciences, Inc. (GBLX) announces a delay in the sale of GB Sciences Louisiana LLC. On September 16, 2019, GB Sciences, Inc. (the "Company"), filed a Current Report on Form 8-K disclosing that the Company had signed a term sheet with K2 Logic, LLC ("K2") pursuant to which K2 will pursue the purchase of the Company's 50% ownership interest in GB Science Louisiana, LLC for $8,000,000 in cash and earn out provisions for up to an additional $8,000,000. GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.
  • GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of DirectorsOctober 31, 2019LAS VEGAS, Oct. 31, 2019 /PRNewswire/ — GB Sciences, Inc. (GBLX) is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector with deep expertise in patents and intellectual property. Mr. DeFrank brings a host of skills and experience beneficial to the Company.